Respreeza

ATC：B02AB02

治疗领域：Genetic Diseases, Inborn;Lung Diseases

药理分类：Antihemorrhagics

修订号：15 · 最新影响 PI 的程序：VR/0000245783

适应症（原文）：Respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ). Patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.